基因组重排的委内瑞拉马脑炎疫苗可抵抗回复突变并在气溶胶攻毒后保护非人灵长类免受病毒血症
评估V4020减毒活疫苗(结构基因重排)在食蟹猴中的免疫原性与对气溶胶攻击的保护效果。接种一或两剂(含肌内途径)后产生高水平中和抗体,无病毒血症或明显不良反应;气溶胶攻击后未检出病毒血症,显示保护作用。
要点
- V4020疫苗病毒基因组含结构基因重排及TC83减毒突变,E2-120Arg工程化替换防止回复突变。
- 食蟹猴接种一或两剂V4020(含肌内途径)后产生高水平中和抗体,无病毒血症或明显不良反应。
- 气溶胶攻击后食蟹猴未检出病毒血症,显示V4020疫苗的保护效果。
核心结论
- V4020减毒活疫苗在食蟹猴中具有免疫原性,并对气溶胶攻击的委内瑞拉马脑炎病毒显示保护效果。
研究设计与样本
- 在非人灵长类模型(食蟹猴)中评估V4020疫苗的免疫原性与对野生型VEEV气溶胶攻击的保护效果。
主要发现
- 源自pMG4020转染Vero细胞的V4020疫苗病毒经NGS分析未检测到基因回复突变。
- 食蟹猴接种一或两剂V4020(含肌内途径)后确认高水平病毒中和抗体,无病毒血症或明显不良反应。
- 气溶胶攻击后食蟹猴未检出病毒血症,显示V4020疫苗的保护效果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Live-attenuated V4020 vaccine for Venezuelan equine encephalitis virus (VEEV) containing attenuating rearrangement of the virus structural genes was evaluated in a non-human primate model for immunogenicity and protective efficacy against aerosol challenge with wild-type VEEV. The genomic RNA of V4020 vaccine virus was encoded in the pMG4020 plasmid under control of the CMV promoter and contained the capsid gene downstream from the glycoprotein genes. It also included attenuating mutations from the VEE TC83 vaccine, with E2-120Arg substitution genetically engineered to prevent reversion mutations. The population of V4020 vaccine virus derived from pMG4020-transfected Vero cells was characterized by next generation sequencing (NGS) and indicated no detectable genetic reversions. Cynomolgus macaques were vaccinated with V4020 vaccine virus. After one or two vaccinations including by intramuscular route, high levels of virus-neutralizing antibodies were confirmed with no viremia or apparent adverse reactions to vaccinations. The protective effect of vaccination was evaluated using an aerosol challenge with VEEV. After challenge, macaques had no detectable viremia, demonstrating a protective effect of vaccination with live V4020 VEEV vaccine.
引用
- Tretyakova I, Plante KS, Rossi SL, et al. Venezuelan equine encephalitis vaccine with rearranged genome resists reversion and protects non-human primates from viremia after aerosol challenge. Vaccine. 2020. PMID: 32085953. doi:10.1016/j.vaccine.2020.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。